Evidence map›Paper›PMID 25921528›Full record

ArticleCell reports2015

Neddylation promotes ubiquitylation and release of Ku from DNA-damage sites.

Jessica S Brown, Natalia Lukashchuk, Matylda Sczaniecka-Clift, Sébastien Britton, Carlos le Sage, Patrick Calsou, Petra Beli, Yaron Galanty, Stephen P Jackson

Open access · goldAbstract read
In one paragraph

Article in Cell reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers.

0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

82 citing papers in PubMed, 128 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. ER-associated degradation ligase HRD1 links ER stress to DNA damage repair by modulating the activity of DNA-PKcs.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Identification of the main barriers to Ku accumulation in chromatin.bioRxiv : the preprint server for biology · 2024
    Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

22 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Jessica S BrownThe Wellcome Trust and Cancer Research UK Gurdon Institute, University of Cambridge, Cambridge 2 1QN, UK.
Natalia LukashchukThe Wellcome Trust and Cancer Research UK Gurdon Institute, University of Cambridge, Cambridge 2 1QN, UK.
Matylda Sczaniecka-CliftThe Wellcome Trust and Cancer Research UK Gurdon Institute, University of Cambridge, Cambridge 2 1QN, UK.
Sébastien BrittonThe Wellcome Trust and Cancer Research UK Gurdon Institute, University of Cambridge, Cambridge 2 1QN, UK; Institut de Pharmacologie et de Biologie Structurale, CNRS, Université de Toulouse-Université Paul Sabatier, Equipe Labellisée Ligue contre le Cancer, 31077 Toulouse, France.
Carlos le SageThe Wellcome Trust and Cancer Research UK Gurdon Institute, University of Cambridge, Cambridge 2 1QN, UK.
Patrick CalsouInstitut de Pharmacologie et de Biologie Structurale, CNRS, Université de Toulouse-Université Paul Sabatier, Equipe Labellisée Ligue contre le Cancer, 31077 Toulouse, France.
Petra BeliInstitute of Molecular Biology (IMB), 55128 Mainz, Germany. Electronic address: p.beli@imb-mainz.de.
Yaron GalantyThe Wellcome Trust and Cancer Research UK Gurdon Institute, University of Cambridge, Cambridge 2 1QN, UK. Electronic address: y.galanty@gurdon.cam.ac.uk.
Stephen P JacksonThe Wellcome Trust and Cancer Research UK Gurdon Institute, University of Cambridge, Cambridge 2 1QN, UK. Electronic address: s.jackson@gurdon.cam.ac.uk.
Wellcome Trust · GBInstitut de Pharmacologie et de Biologie Structurale · FRInstitute of Molecular Biology · DEUniversité Fédérale de Toulouse Midi-Pyrénées · FRUniversity of Cambridge · GB

Funding

Cancer Research UK 11224Cancer Research UK 18796Cancer Research UK C6/A11224Wellcome Trust WT083416Wellcome Trust WT092096
6 · The paper itself

Abstract

The activities of many DNA-repair proteins are controlled through reversible covalent modification by ubiquitin and ubiquitin-like molecules. Nonhomologous end-joining (NHEJ) is the predominant DNA double-strand break (DSB) repair pathway in mammalian cells and is initiated by DSB ends being recognized by the Ku70/Ku80 (Ku) heterodimer. By using MLN4924, an anti-cancer drug in clinical trials that specifically inhibits conjugation of the ubiquitin-like protein, NEDD8, to target proteins, we demonstrate that NEDD8 accumulation at DNA-damage sites is a highly dynamic process. In addition, we show that depleting cells of the NEDD8 E2-conjugating enzyme, UBE2M, yields ionizing radiation hypersensitivity and reduced cell survival following NHEJ. Finally, we demonstrate that neddylation promotes Ku ubiquitylation after DNA damage and release of Ku and Ku-associated proteins from damage sites following repair. These studies provide insights into how the NHEJ core complex dissociates from repair sites and highlight its importance for cell survival following DSB induction.

Indexed as

DNA DamageAntigens, NuclearCell LineCell SurvivalCyclopentanesDNA-Binding ProteinsDNA End-Joining RepairHistonesHumansKu AutoantigenNEDD8 ProteinProtein BindingProtein Structure, TertiaryProteomicsPyrimidinesRadiation, IonizingAntigens, NuclearCyclopentanesDNA-Binding ProteinsH2AX protein, humanHistonesKu AutoantigenNEDD8 ProteinNEDD8 protein, humanpevonedistatPyrimidinesRNA, Small InterferingUBE2M protein, humanUbiquitin-Conjugating EnzymesUbiquitinsXrcc6 protein, human

Identifiers

PMID25921528
PMCPMC4431666
OpenAlexW2076798160

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.